Investor
Ideas #Potcasts, #Cannabis News and #Stocks on the Move; Episode 448 (CSE: $TER.C)
(CSE: $CURA.C) (OTC: $HEMP)
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2020/073120-StocksToWatch.mp3
Read
this in full at https://www.investorideas.com/news/2020/cannabis-potcasts/07311TER-CURA-HEMP.asp
Hear the investor ideas potcast on Spotify
Hear Investor ideas cannabis potcast on iTunes
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com
"Potcast" featuring cannabis news, stocks to watch as well as
insights from thought leaders and experts.
In
today’s podcast we look at a few public and private company announcements.
Open
Book Extracts announced its
expansion of operations and distribution channels into Asia, Israel and most
recently, South Africa.
To serve a recently estimated $6.4
billion market opportunity for cannabis in South Africa, OBX was named a
principal distribution partner of Peter Bodill Agencies LTD of South Africa.
With more than 30 years in the agency/distribution business in South Africa,
Peter Bodill Agencies represents manufacturers that specialize in supplying
some of the world’s finest products, such as vitamin mixes, probiotics and
industrial ingredients throughout the entire country. OBX joins global
commercial distribution partner, Prinova Nagase Group, in a short list of
principals vetted and approved by Peter Bodill Agencies for South African
distribution.
“Quality, safety and reliability are
essential in the burgeoning South Africa cannabis market,” stated Peter Bodill,
director of Peter Bodill Agencies LTD. “The caliber of the team and products
from Open Book Extracts has exceeded our expectations. We are excited to be
able to provide its high-quality CBD products, innovative cannabinoid blends
and pure rare cannabinoids to our clients.”
In addition to the South Africa
distribution channel, OBX expanded its footprint into Asia, appointing Laurie
Goldberg as OBX Asia’s chief executive officer. Goldberg, who founded and
recently sold AmeriCraft Imports Limited, a Hong Kong-based craft beer importer
and distributor, will lead expansion efforts into the Asia market.
“With the demand for CBD products in
Asia growing rapidly, it is paramount for leading brands to have a reputable,
quality supplier like Open Book Extracts,” stated Goldberg. “The fact that OBX
is cGMP certified, able to deliver pharma-grade purity levels and is well
versed in global market distribution ensures that we will meet the Asian market
demand for high-quality, safe cannabinoid products.”
“We’re thrilled to expand our
footprint to provide safe and efficacious cannabinoid products worldwide,”
stated Dave Neundorfer, chief executive officer at OBX. “While we are glad to
see countries roll out regulations to permit non-THC cannabinoids in food,
beverages and personal care products, we’re also planning clinical trials for
safety and efficacy to support dietary supplement and pharmaceutical
registrations.”
The establishment of global
distribution channels follows closely on the heels of Open Book Extracts’
recent acquisition of Chilmark Labs and its Israeli affiliate, Beetlebung
Pharma Ltd., enabling the manufacturing of high-purity rare and minor
cannabinoids at commercial scale, and further unlocking the therapeutic
potential of cannabinoid-based products.
TerrAscend
Corp. (CSE:TER) (OTCQX:
TRSSF) today announced that it
has officially opened its seventh retail dispensary location. The new 4,200
square foot Apothecarium dispensary, located at 2312 Telegraph Ave, Berkeley,
CA is the company's fourth California dispensary, and TerrAscend's seventh
dispensary nationwide.
The Apothecarium Berkeley is a
full-service recreational and medical cannabis dispensary featuring a stylish,
upscale design and a staff of highly trained cannabis consultants to assist
guests. The store carries a wide variety of cannabis products, including
edibles, flowers, vaping products, concentrates, capsules, tinctures, topicals,
and ancillary products. The new location offers online ordering at
apothecarium.com for pickup and delivery.
"We are excited to begin
serving our East Bay customers from a beautiful new location on Telegraph
Avenue," said Ryan Hudson, CEO, and co-founder of The Apothecarium.
"At The Apothecarium, our focus is on education. We aim to provide
one-on-one consultations that help our patients and customers find the right
products for their needs. Whether they are looking for help in-person, by phone
or via web chat, our cannabis consultants are here to help."
"For nearly a decade The
Apothecarium has set the standard for dispensary design and customer
service," said Jason Ackerman, CEO of TerrAscend. "The Apothecarium
Berkeley is raising the bar again with a refined look and upgraded technology
that brings the dispensary's famous consultations and cannabis education
classes online. We're delighted to expand our footprint; Berkeley is our fourth
California dispensary and our first in the East Bay."
The Apothecarium Berkeley is
designed to be comfortable and easy to navigate for seniors, first-time
dispensary visitors, and patients with serious medical conditions. The dispensary
features The Apothecarium's typical mix of neo-Victorian furnishings, modern
touches, and plenty of natural light. The store was designed by the same team
behind The Apothecarium's three San Francisco dispensaries: architect Vincent
Gonzaga and the interior design firm, Urban Chalet.
All Apothecarium dispensaries have
implemented strict safety standards to protect guests and team members. Our
California safety protocols include strict social distancing inside and outside
the dispensaries, a mask requirement for everyone inside the dispensaries, no
contact check-in procedures and ongoing sanitizing throughout the day.
Curaleaf
Holdings, Inc. (CSE:
CURA) (OTCQX:
CURLF) announced the
launch of Curaleaf Sublingual Tablets in Florida. These cube-shaped,
berry-flavored bites will provide the state's medical patients with a discreet,
sugar-free yet fruity alternative form of medication.
Curaleaf's new Sublingual Tablets,
which will be in 30-piece jars, contain 5mg of high-quality cannabis oil per
piece, which allows patients to manage their treatment plan with confidence and
ease. Each bite, which is made to be ingested orally or sublingually, is
translucent in color and features a refreshing "Arctic Berry" flavor.
The new product will be sold at all of the Company's 28 operating dispensaries
in Florida with a phased roll-out between August 8th - August 20th. Limited
quantities will be released to pre-existing loyalty patients beginning
tomorrow, July 30th. For more information on the product roll-out cadence,
please visit
https://curaleaf.com/blog/curaleaf-sublingual-tablets.
"The demand for alternative
cannabis form functions in Florida has been mounting for years, and we are
thrilled to offer our patients an exciting new product -- Sublingual
Tablets," said Joe Lusardi, Chief Executive Officer at Curaleaf. "Our
success is driven by listening to and meeting the needs of our patients, and we're
incredibly proud to be first to market in Florida with this new option in
cannabis medicine. By providing high-quality products in a variety of
administration routes, we are better positioned to improve our patients' lives,
which has been our mission since day one."
Earlier this summer, Curaleaf began
selling "Shorties," a pre-roll flower product, in response to the
requests of their Florida patients. As an additional offering to the classic 1g
pre-roll, patients can now enjoy freshly harvested flower by way of these
conveniently sized .4g pre-rolls.
Florida's continued growth in
patient registration makes it one of the nation's fastest-growing medical
cannabis markets in the country. Currently, there are over 377,000 medical
patients enrolled in the Florida program - about 1.7% of the state's population
- with approximately 5,000 new patients enrolling each week. To ensure the best
possible service to the increasing number of medical patients, Curaleaf is in
the process of expanding its Florida presence, adding to current grow capacity
and planning to open at least five new dispensaries by Q4.
During the COVID-19 pandemic,
cannabis businesses have been deemed an essential service in most states,
including Florida. Curaleaf remains committed to serving patients and customers
with the products they rely on while implementing heightened safety and
hygienic measures in all its facilities.
Curaleaf's dispensary regular
operating hours remain in effect, and free statewide delivery is always
available for Florida medical patients. Throughout the year, discounts are
offered to senior citizens, military veterans, pediatric patients, and
recipients of government financial assistance. Please visit
www.curaleaf.com/locations to find a dispensary near you.
Geocann announced that
the company has commercialized the first oral dose application that overcomes
the well-known bioavailability challenges of science-backed, key ingredients
found in popular immunity support products. The multi-patented VESIsorb®
delivery system provides the much-needed solution that turns the following
poorly absorbed individual compounds into a synergistic, 4-in-1 formulation
with dramatic improvements in absorption and bioavailability:
● 50 mg
curcumin from turmeric root;
●
15 mg cannabidiol (CBD) from broad spectrum
hemp extract;
●
7 mg beta-caryophyllene (BCP) that has
received FDA GRAS status; and
● 200 IU
vitamin D3.
“These
ingredients have been strategically selected for their immunity support and
anti-inflammatory properties, but are notorious for showing limited
bioavailability due to their lipophilicity and extensive first-pass
metabolism,” said Anthony Petraglia, M.D., Chief Medical Officer. “With a
successful track record over the past fifteen years, VESIsorb® has
consistently demonstrated its ability to mitigate these negative effects while
significantly improving the pharmacokinetic performance of natural ingredients.
To put it simply, bioavailability is the key to providing an immunity support
product that delivers its desired health benefits.”
This
formulation milestone comes on the heels of a study that was published in the
peer-reviewed journal, Molecules,
showcasing the numerous advantages of broad spectrum hemp extract formulated
with VESIsorb® to that of the same broad spectrum hemp extract
combined with medium chain triglycerides (MCT) oil. Key findings included that
an important subgroup showed statistically significant improvements for all
measured pharmacokinetic parameters, including a 712% increase in maximal
plasma CBD concentration (Cmax), a 449% improvement in total CBD exposure over
time [area under the curve (AUC)], and a 400% improvement in time to peak
absorption (Tmax).
“Geocann
has a strategic focus to deliver cannabinoid and terpene products with an
unmatched body of supporting scientific evidence that address the most pressing
health concerns,” said Sam Davidson, Chief Operating Officer. “The marketplace
demand for natural immunity support products is unprecedented, and the
relationship between a healthy immune system and a strong endocannabinoid
system (ECS) is well-documented. More than ever, we are committed to pioneering
these innovative solutions with our technical formulation expertise, rigorous
product development protocol, and global distribution infrastructure.”
Geocann
has the exclusive global rights to the patented VESIsorb® drug delivery
technology for cannabinoids, terpenes, and flavonoid formulations. The company
is strategically partnering with leading lifestyle brands that share a
commitment to superior product safety, quality, and performance. The VESIsorb®
drug delivery system has been successfully applied to a wide range of cannabis
based product applications, including soft gel and hard shell capsules,
functional foods (e.g. gummies) and beverages, powder systems, tinctures,
sublingual sprays, and topically applied formulations.
Hemp,
Inc. (OTC:
HEMP) commended
Congress for approving an amendment to the National Defense Authorization Act
(NDAA) permitting military service members to use CBD and hemp-derived
products.
The amendment supersedes months of
confusion surrounding cannabidiol (CBD) policy earlier this year and addresses
policies across military organizations following the legalization of hemp in
the 2018 Farm Bill. The amendment also includes a measure allowing heads of
military branches to issue reenlistment waivers to members of the armed forces
who admit to using cannabis.
The approved measure is also
celebrated by Hemp Inc.’s strategic hemp growing partner Veterans Village Kins Community in Arizona which is designed to
grow hemp for CBD products that benefit veterans, generate revenues for the
residents, and to support the holistic healing and learning center at the heart
of the community.
“This is a step in the right
direction for cannabis policy reform provisions and we’re very pleased that
Congress has taken the initiative to allow military members to utilize the
natural benefits of hemp to remedy the mental and physical effects of serving
our country,” said Hemp, Inc. CEO Bruce Perlowin. “Working with our veteran
partners at Veteran Village Kins Community in Arizona, Inc. we can see the good
that CBD has on former military service members and this only illustrates the
therapeutic and preventative effects it can have on active members as well.”
According to the Department of
Defense Suicide Prevention (DoDSER) 2017 annual report, there were 1,397
non-fatal suicide attempts by active-duty service members. However, a 2015
study titled ‘Cannabidiol as a Potential Treatment for Anxiety Disorders’
showed CBD usage to be most effective in helping people deal with traumatic
events within an hour of the experience, suggesting that using CBD while on
active duty could probably decrease the development of PTSD and severe anxiety
before it is too late.
Investor ideas reminds all
listeners to read our disclaimers and disclosures on the Investorideas.com
website and that this podcast is not an endorsement to buy products or services
or securities. Investors are reminded all investment involves risk and possible
loss of investment.
Learn more about
our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on Spotify
To hear more
Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com
podcasts are also available on iTunes,
Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified
word mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About Investorideas.com - News that
Inspires Big Investing Ideas
Investorideas.com
is a recognized news source publishing third party news, research and original
financial content. Learn about investing in stocks and sector trends with our
news alerts, articles, podcasts and
videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water,
renewable energy and more. Investor Idea’s original branded content includes
the following podcasts and columns : Crypto Corner , Play
by Play sports and stock news column, Investor Ideas
Potcasts Cannabis News and Stocks on the Move podcast and
column, Cleantech
and Climate Change , Exploring
Mining the AI
Eye .
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other
news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations
of each country. Please read Investorideas.com privacy policy:
https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of
cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow
us on Facebook https://www.facebook.com/Investorideas
Follow
us on YouTube https://www.youtube.com/c/Investorideas
Download
our Mobile App for
iPhone and Android
Join
our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800
665 0411
Get more Cannabis Stock Investor Ideas – news,
articles, podcasts and
stock directory
No comments:
Post a Comment